A decrease of IL-1β immunoreactivity was attributed to the beneficial effect of higher doses of SCFAs (30 mg/kg and 100 mg/kg) (Figure 5M,N for SP; Figure 5P,Q for SB), maintaining intestinal integrity following NTG-induced migraine. This evidence concerns the gene IL1B and migraine disorder.